1-(2-Methoxyethyl)pyrrolidin-3-amine | 1096335-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(2-Methoxyethyl)pyrrolidin-3-amine
• CAS: 1096335-57-7
• 化学式: C₇H₁₆N₂O
• mdl: MFCD11640980
• 分子量: 144.21
• InChiKey: SRWRVWNAMHIATJ-UHFFFAOYSA-N

物化性质

• 沸点：
  188.9±30.0 °C(Predicted)
• 密度：
  0.975±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• [EN] ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSÉS ANTINÉOPLASIQUES, COMPOSITIONS ET PROCÉDÉS
  申请人：PROGENRA INC

  公开号：WO2010114881A1

  公开（公告）日：2010-10-07

  Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.

  公开的是新型化合物，这些化合物在治疗上具有用途，特别是在抗肿瘤治疗和其他涉及半胱氨酸蛋白酶抑制的治疗方案中。
• [EN] CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS<br/>[FR] INHIBITEURS DE LA CYTOKINE, EN PARTICULIER DE TNF-ALPHA
  申请人：PHARMACOPEIA INC

  公开号：WO2001047897A1

  公开（公告）日：2001-07-05

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I. Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

  揭示了一种通过抑制p38激酶来阻断细胞因子产生的N-杂环化合物。在一种实施例中，本发明的化合物由式I表示。本发明还揭示了利用本发明化合物治疗与不适当的p38激酶活性或TNF-α表达相关的疾病情况的方法、制备方法和制药组合物。
• ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS
  申请人：Cao Ping

  公开号：US20120114765A1

  公开（公告）日：2012-05-10

  Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.

  本发明涉及一种新型化合物，可用作治疗剂，特别是在抗肿瘤疗法和其他治疗方案中具有半胱氨酸蛋白酶抑制作用的情况下。
• PROCESS FOR PREPARING 4-SUBSTITUTED-1-(2-METHOXYETHYL)PYRROLIDIN-3-AMINE DERIVATIVES
  申请人：Array Biopharma, Inc.

  公开号：EP3564236A1

  公开（公告）日：2019-11-06

  Provided is Compound 1 or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling.

  提供的是化合物 1 或其药学上可接受的盐，它是一种 TrkA 激酶抑制剂，可用于治疗可使用 TrkA 激酶抑制剂治疗的疾病，如疼痛、癌症、炎症和炎症性疾病、神经退行性疾病、某些传染性疾病、Sjogren 综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎、盆腔疼痛综合征、与骨重塑调节失衡有关的疾病，以及结缔组织生长因子异常信号传导导致的疾病。